Lyell Immunopharma Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Lyell Immunopharma şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.6%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.6%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

Oct 25

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Apr 16

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Feb 23

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Nov 09

Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher

Aug 29

We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Aug 11

Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans

Dec 15

Lyell Immunopharma gets FDA nod to start phase 1 trial of its cancer therapy LYL845

Oct 06

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Sep 12

News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts

Aug 08

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Apr 29

We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Dec 31

Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation

Sep 17

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: LYEL şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: LYEL şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Lyell Immunopharma Piyasaya Karşı Temettü Getirisi

LYEL temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (LYEL)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (LYEL) (3 yıla kadar)	0%

Önemli Temettü: LYEL şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, LYEL şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: LYEL şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: LYEL herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Lyell Immunopharma Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Third quarter 2024 earnings released: US$0.17 loss per share (vs US$0.20 loss in 3Q 2023)

Lyell Immunopharma, Inc. (NasdaqGS:LYEL) completed the acquisition of ImmPACT Bio USA Inc.

Lyell Immunopharma, Inc. (NasdaqGS:LYEL) entered into an agreement and plan of merger to acquire ImmPACT Bio USA Inc. for $87.5 million.

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

Lyell Immunopharma, Inc. (NasdaqGS:LYEL) entered into an agreement and plan of merger to acquire ImmPACT Bio USA Inc. for $87.5 million.

Consensus revenue estimates increase by 52,616%

Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.26 loss in 2Q 2023)

Price target decreased by 44% to US$3.67

Consensus EPS estimates fall by 0.05%

Lyell Immunopharma Reports Dose-Dependent Clinical Activity from Phase 1 Trial of Lyl797, A Ror1-Targeted Car-T Cell Product Candidate Enhanced with Its Proprietary Anti-Exhaustion Technology

Consensus revenue estimates increase by 400%

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.27 loss in 1Q 2023)

Insufficient new directors

New minor risk - Shareholder dilution

Lyell Immunopharma, Inc., Annual General Meeting, Jun 14, 2024

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Full year 2023 earnings released: US$0.94 loss per share (vs US$0.74 loss in FY 2022)

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Phoenix Biotech Acquisition Corp. (NasdaqGM:PBAX) completed the acquisition of CERo Therapeutics, Inc.

New major risk - Share price stability

Consensus revenue estimates increase by 378%

Price target decreased by 7.1% to US$6.50

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Third quarter 2023 earnings released: US$0.20 loss per share (vs US$0.28 loss in 3Q 2022)

Lyell Immunopharma, Inc. Presents New Nonclinical Data at 38th Annual Meeting of SITC on Innovations Designed to Shorten Tumor Infiltrating Lymphocyte Manufacturing, LYL119 as Well as Data on New Technologies and Design of its Two Clinical Trials in Progress

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's Car T-Cell Therapy on Cellares' Cell Shuttle Platform

Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher

Consensus revenue estimates increase by 25%

Founder & Executive Chairman recently sold US$132k worth of stock

Founder & Executive Chairman notifies of intention to sell stock

Consensus revenue estimates decrease by 96%, EPS upgraded

We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Second quarter 2023 earnings released: US$0.26 loss per share (vs US$0.15 loss in 2Q 2022)

Lyell Immunopharma, Inc. Appoints Matthew Lang as Chief Business Officer

New major risk - Share price stability

Lyell Immunopharma, Inc. Announce Resignation of Rahsaan Thompson as the Chief Legal Officer

Price target decreased by 23% to US$7.25

Consensus revenue estimates decrease by 87%, EPS upgraded

First quarter 2023 earnings released: US$0.27 loss per share (vs US$0.28 loss in 1Q 2022)

Price target decreased by 7.8% to US$9.40

Price target decreased by 9.3% to US$9.80

Full year 2022 earnings released: US$0.74 loss per share (vs US$1.84 loss in FY 2021)

Lyell Immunopharma, Inc. Appoints Lynn Seely as President

Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates increase by 18%

High number of new directors

Price target decreased to US$12.80

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Lyell Immunopharma Announces Fda Clearance of Its Ind for Lyl845, A Til Product Candidate Enhanced with Its Novel Epigenetic Reprogramming Technology for Solid Tumors

Lyell Immunopharma gets FDA nod to start phase 1 trial of its cancer therapy LYL845

Founder & Executive Chairman recently sold US$71k worth of stock

Lyell Immunopharma, Inc. Announces the Appointment of Rahsaan W. Thompson as Chief Legal Officer

Founder & Executive Chairman notifies of intention to sell stock

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Consensus forecasts updated

News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts

Second quarter 2022 earnings released: US$0.15 loss per share (vs US$1.47 loss in 2Q 2021)

Lyell Immunopharma, Inc.(NasdaqGS:LYEL) dropped from Russell 2000 Growth Index

Consensus revenue estimates increase by 28%

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Lyell Immunopharma to Present Preclinical Data for Two Product Candidates in Clinical Development at ASGCT Annual Meeting

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

High number of new directors

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 37%

Independent Director exercised options to buy US$6.9m worth of stock.

Lyell Immunopharma Announces Executive Changes

Lyell Immunopharma, Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug for LYL132

High number of new directors

We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Lyell Immunopharma, Inc. Announces FDA Clearance of its IND for LYL797

Lyell Immunopharma, Inc. Announces cGMP Qualification of LyFE™ Manufacturing Center in Advance of Initiating Clinical Programs

Third quarter 2021 earnings released: US$0.20 loss per share

Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation

Lyell Immunopharma, Inc. has completed an IPO in the amount of $425 million.